CLINICAL TRIALS PROFILE FOR PF-07081532
✉ Email this page to a colleague
Clinical Trials for PF-07081532
| Trial ID | Title | Status | Sponsor | Phase | Summary |
|---|---|---|---|---|---|
| NCT04148209 ↗ | Study of Single Ascending Doses of PF-07081532 in Healthy Adult Participants | Completed | Pfizer | Phase 1 | The purpose of this study is to evaluate the safety, tolerability and pharmacokinetics (PK) of single ascending oral doses of PF-07081532 in healthy adult participants. |
| NCT04305587 ↗ | Multiple Escalating Oral Doses Study of PF-07081532 in Adult Participants With Type 2 Diabetes Mellitus | Completed | Pfizer | Phase 1 | This is a randomized, placebo-controlled, double-blind (investigator- and participant-blinded), sponsor-open, dose-escalating study of PF-07081532 in patients with Type 2 diabetes on metformin (Parts A and C). The study may also enroll non-diabetic participants with obesity (Part B). Study participants will receive an investigational product or placebo every day for up to 28 days (Part A) or up to 42 days (Part B, optional; Part C, optional). The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics (PK) of multiple oral doses of PF-07081532 in participants with inadequately controlled T2DM on metformin and optionally in non-diabetic obese participants. |
| NCT05158244 ↗ | A Phase 1 Study of Multiple Oral Doses of PF-07081532 in Adult Participants With Type 2 Diabetes Mellitus | Not yet recruiting | Pfizer | Phase 1 | This is a Phase 1, randomized, placebo-controlled, double-blind (investigator- and participant-blinded), sponsor-open study of PF-07081532. Study participants will receive the investigational product or placebo every day for 42 days. The purpose of the study is to evaluate the safety, tolerability and pharmacokinetics (PK) of multiple oral doses of PF-07081532 in participants with inadequately controlled type 2 diabetes mellitus, on metformin and optionally in non-diabetic participants with obesity. |
| NCT05478603 ↗ | A Study to Investigate the Effects of Hepatic Impairment on the Pharmacokinetics of PF-07081532 | Not yet recruiting | Pfizer | Phase 1 | The primary purpose of this study is to characterize the effect of varying degrees of hepatic impairment on the plasma pharmacokinetics (PK) of PF-07081532 following administration of a single oral dose of PF-07081532. |
| NCT05510245 ↗ | A Study to Investigate the Effects of Renal Impairment on the Pharmacokinetics of PF-07081532 | Not yet recruiting | Pfizer | Phase 1 | A Study to Investigate the Effects of Renal Impairment on the Pharmacokinetics of PF-07081532, one 20 mg tablet administered orally. |
| NCT05579977 ↗ | Trial to Learn About the Study Medicine (PF-07081532) and Rybelsus in People With Type 2 Diabetes and Separately PF-07081532 in People With Obesity | Not yet recruiting | Pfizer | Phase 2 | The purpose of this study is to find out if PF-07081532 ("the active study drug"), is safe and helps treat people with obesity without diabetes to lose weight, and people with diabetes to keep their blood sugar in good control. Individuals diagnosed with diabetes that are on metformin or individuals with obesity without diabetes will be included in the study. Those participating in the diabetes part of the study, will receive either active study drug, placebo, or an approved treatment called Rybelsus. Those in the obesity part of the study, will receive either active study drug or placebo. The study will last for about 36 weeks except for the first 25% of the participants that enter in which case the study will last for approximately 48 weeks. during this time there will be visits every 4 weeks with phone calls in between. |
| NCT05652647 ↗ | A Study to Understand How the Study Medicine (PF-07081532) is Processed and Eliminated in Healthy Men. | Not yet recruiting | Pfizer | Phase 1 | The purpose of this clinical trial is to learn about how much PF-07081532 will be taken up and processed by healthy male participants. The study consists of two parts, called study periods. In Period 1, participants will take one dose of PF-07081532 by mouth. In Period 2, participants will take one dose by mouth and one dose as an injection through a vein at the study clinic. In Period 1, participants will stay at the clinic site for up to 21 days. In Period 2, they will stay at the clinic site for 7 days. During their stays, participants will have their blood, urine, and feces collected by the study doctors several times. We will measure the level of PF-07081532 in participants' blood, urine, and feces samples. This will help us know how much the study medicine is getting taken in by the body. At the end of the study, participants will be contacted by phone to check in. Participants will be involved in this study for about 12 weeks. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Summary |
Clinical Trial Conditions for PF-07081532
Condition Name
Clinical Trial Locations for PF-07081532
Trials by Country
Clinical Trial Progress for PF-07081532
Clinical Trial Phase
Clinical Trial Sponsors for PF-07081532
Sponsor Name
